NEUROCRINE BIOSCIENCES INC Gain (Loss) on Extinguishment of Debt
NEUROCRINE BIOSCIENCES INC (NBIX) reported Gain (Loss) on Extinguishment of Debt of -$2.20 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2026-02-11
- NEUROCRINE BIOSCIENCES INC gain (loss) on extinguishment of debt for the quarter ending 2024-12-31 was $0.00.
- NEUROCRINE BIOSCIENCES INC gain (loss) on extinguishment of debt for the quarter ending 2024-09-30 was $0.00.
- NEUROCRINE BIOSCIENCES INC gain (loss) on extinguishment of debt for the quarter ending 2023-12-31 was $0.00.
- NEUROCRINE BIOSCIENCES INC gain (loss) on extinguishment of debt for the quarter ending 2023-09-30 was $0.00.
- NEUROCRINE BIOSCIENCES INC gain (loss) on extinguishment of debt for fiscal 2024 was -$2.20M.
- NEUROCRINE BIOSCIENCES INC gain (loss) on extinguishment of debt for fiscal 2023 was $0.00.
- NEUROCRINE BIOSCIENCES INC gain (loss) on extinguishment of debt for fiscal 2022 was -$70.00M.
- NEUROCRINE BIOSCIENCES INC gain (loss) on extinguishment of debt for fiscal 2021 was $0.00.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $0.00 derived: sum of 2 quarters · filed 2026-02-11 | -$2.20M 10-K · filed 2026-02-11 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | -$2.20M 10-Q · filed 2025-10-28 | ||
| 2024-06-30 | -$2.20M 10-Q · filed 2025-07-30 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-09 | $0.00 derived: sum of 2 quarters · filed 2024-02-09 | $0.00 derived: sum of 3 quarters · filed 2024-02-09 | $0.00 10-K · filed 2024-02-09 |
| 2023-09-30 | $0.00 10-Q · filed 2023-10-31 | $0.00 derived: sum of 2 quarters · filed 2023-10-31 | $0.00 10-Q · filed 2023-10-31 | $0.00 derived: sum of 4 quarters · filed 2024-02-09 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-01 | $0.00 10-Q · filed 2023-08-01 | $0.00 derived: sum of 3 quarters · filed 2024-02-09 | $0.00 derived: sum of 4 quarters · filed 2024-02-09 |
| 2023-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2024-02-09 | $0.00 derived: sum of 2 quarters · filed 2024-02-09 | $0.00 derived: sum of 3 quarters · filed 2024-02-09 | -$70.00M derived: sum of 4 quarters · filed 2024-02-09 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-09 | $0.00 derived: sum of 2 quarters · filed 2024-02-09 | -$70.00M derived: sum of 3 quarters · filed 2024-02-09 | -$70.00M 10-K · filed 2024-02-09 |
| 2022-09-30 | $0.00 10-Q · filed 2023-10-31 | -$70.00M derived: sum of 2 quarters · filed 2023-10-31 | -$70.00M 10-Q · filed 2023-10-31 | |
| 2022-06-30 | -$70.00M 10-Q · filed 2023-08-01 | -$70.00M 10-Q · filed 2023-08-01 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-09 | $0.00 derived: sum of 2 quarters · filed 2024-02-09 | $0.00 derived: sum of 3 quarters · filed 2024-02-09 | $0.00 10-K · filed 2024-02-09 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-01 | $0.00 derived: sum of 2 quarters · filed 2022-11-01 | $0.00 10-Q · filed 2022-11-01 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | ||
| 2020-12-31 | -$18.40M 10-K · filed 2023-02-09 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-11 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |